Drug Profile
FIN 524
Alternative Names: FIN-524; TAK-524Latest Information Update: 29 Aug 2022
Price :
$50
*
At a glance
- Originator Finch Therapeutics
- Developer Finch Therapeutics Group
- Class Bacteria; Probiotics
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases